Strengthening Cyclotron Produced Gallium-68 Radiopharmaceutical Manufacturing Capacity at CIRC

We have successfully installed our second iPHASE MultiSyn module, completing our integrated production platform for cyclotron produced Gallium 68 radiopharmaceuticals and establishing a streamlined, high capacity manufacturing workflow.

Within this configuration, the first MultiSyn module is dedicated to the purification of cyclotron produced Gallium 68, ensuring a high purity radionuclide input. The purified Gallium 68 is subsequently transferred to the second MultiSyn module for fully automated radiolabelling of a broad range of precursors, including peptides and other biomolecules.

Cyclotron produced Gallium 68 offers significant advantages over generator derived material. It enables substantially higher activity yields, supports larger patient volumes and potential regional distribution, and allows production schedules to be aligned with clinical demand rather than generator decay constraints.

This installation represents a strategic advancement toward a scalable, efficient, and future ready production model for Gallium 68 based PET radiopharmaceuticals, further strengthening our ability to meet the growing clinical demand in Singapore.